Your browser doesn't support javascript.
loading
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Meagher, Nicola S; Wang, Linyuan; Rambau, Peter F; Intermaggio, Maria P; Huntsman, David G; Wilkens, Lynne R; El-Bahrawy, Mona A; Ness, Roberta B; Odunsi, Kunle; Steed, Helen; Herpel, Esther; Anglesio, Michael S; Zhang, Bonnie; Lambie, Neil; Swerdlow, Anthony J; Lubinski, Jan; Vierkant, Robert A; Goode, Ellen L; Menon, Usha; Toloczko-Grabarek, Aleksandra; Oszurek, Oleg; Bilic, Sanela; Talhouk, Aline; García-Closas, Montserrat; Wang, Qin; Tan, Adeline; Farrell, Rhonda; Kennedy, Catherine J; Jimenez-Linan, Mercedes; Sundfeldt, Karin; Etter, John L; Menkiszak, Janusz; Goodman, Marc T; Klonowski, Paul; Leung, Yee; Winham, Stacey J; Moysich, Kirsten B; Behrens, Sabine; Kluz, Tomasz; Edwards, Robert P; Gronwald, Jacek; Modugno, Francesmary; Hernandez, Brenda Y; Chow, Christine; Kelemen, Linda E; Keeney, Gary L; Carney, Michael E; Natanzon, Yanina; Robertson, Gregory; Sharma, Raghwa.
  • Meagher NS; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
  • Wang L; Prince of Wales Clinical School. UNSW Sydney, Sydney, NSW, Australia.
  • Rambau PF; Adult Cancer Program. Lowy Cancer Research Centre, Sydney, Australia.
  • Intermaggio MP; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
  • Huntsman DG; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
  • Wilkens LR; Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania.
  • El-Bahrawy MA; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
  • Ness RB; Adult Cancer Program. Lowy Cancer Research Centre, Sydney, Australia.
  • Odunsi K; British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada.
  • Steed H; Department of Molecular Oncology, BC Cancer Agency Research Centre, Vancouver, BC, Canada.
  • Herpel E; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Anglesio MS; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Zhang B; Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
  • Lambie N; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Swerdlow AJ; Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Lubinski J; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. Royal Alexandra Hospital, Edmonton, AB, Canada.
  • Vierkant RA; Tissue Bank of the National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
  • Goode EL; Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Menon U; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Toloczko-Grabarek A; Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
  • Oszurek O; NSW Health Pathology. Prince of Wales Hospital, Sydney, NSW, Australia.
  • Bilic S; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Talhouk A; Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
  • García-Closas M; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Wang Q; Department of Health Science Research, Division of Biomedical Statistics and Informatics. Mayo Clinic, Rochester, MN, USA.
  • Tan A; Department of Health Science Research, Division of Epidemiology. Mayo Clinic, Rochester, MN, USA.
  • Farrell R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Kennedy CJ; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Jimenez-Linan M; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Sundfeldt K; Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
  • Etter JL; British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada.
  • Menkiszak J; Division of Cancer Epidemiology and Genetics. National Cancer Institute, Bethesda, MD, USA.
  • Goodman MT; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Klonowski P; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Leung Y; Division of Obstetrics and Gynaecology, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
  • Winham SJ; Western Women's Pathology, Western Diagnostic Pathology, Wembley, Western Australia, Australia.
  • Moysich KB; Prince of Wales Private Hospital, Randwick, NSW, Australia.
  • Behrens S; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
  • Kluz T; Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
  • Edwards RP; Department of Histopathology. Addenbrookes Hospital, Cambridge, UK.
  • Gronwald J; Department of Obstetrics and Gynecology, Sahlgrenska Cancer Center, Inst Clinical Scienses, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Modugno F; Department of Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Hernandez BY; Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Chow C; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
  • Kelemen LE; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Keeney GL; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Carney ME; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
  • Natanzon Y; Histopathology Department, King Edward Memorial Hospital, Perth, Western Australia, Australia.
  • Robertson G; Department of Health Science Research, Division of Biomedical Statistics and Informatics. Mayo Clinic, Rochester, MN, USA.
  • Sharma R; Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Mod Pathol ; 32(12): 1834-1846, 2019 12.
Article en En | MEDLINE | ID: mdl-31239549
ABSTRACT
Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7-/CK20+/CDX2+/PAX8-. This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms). All cases were assessed for SATB2, PAX8 CK7, CK20, and CDX2 expression on tissue microarrays. Expression was scored in a 3-tier system as absent, focal (1-50% of tumor cells) and diffuse ( >50% of tumor cells) and then categorized into either absent/present or nondiffuse/diffuse. SATB2 and PAX8 expression was further evaluated in ovarian tumors from an international cohort of 2876 patients (expansion cohort, including 159 mucinous carcinomas and 46 borderline mucinous tumors). The highest accuracy of an individual marker in distinguishing lower gastrointestinal from ovarian mucinous tumors was CK7 (91.7%, nondiffuse/diffuse cut-off) followed by SATB2 (88.8%, present/absent cut-off). The most effective combination was CK7 and SATB2 with accuracy of 95.3% using the 3-tier interpretation, absent/focal/diffuse. This combination outperformed the standard clinical set of CK7, CK20 and CDX2 (87.5%). Re-evaluation of outlier cases confirmed ovarian origin for all but one case. The accuracy of SATB2 was confirmed in the expansion cohort (91.5%). SATB2 expression was also detected in 15% of ovarian endometrioid carcinoma but less than 5% of other ovarian histotypes. A simple two marker combination of CK7 and SATB2 can distinguish lower gastrointestinal from ovarian primary mucinous tumors with greater than 95% accuracy. PAX8 and CDX2 have value as second-line markers. The utility of CK20 in this setting is low and this warrants replacement of this marker with SATB2 in clinical practice.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Factores de Transcripción / Biomarcadores de Tumor / Adenocarcinoma Mucinoso / Proteínas de Unión a la Región de Fijación a la Matriz / Queratina-7 Tipo de estudio: Diagnostic_studies Límite: Female / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Factores de Transcripción / Biomarcadores de Tumor / Adenocarcinoma Mucinoso / Proteínas de Unión a la Región de Fijación a la Matriz / Queratina-7 Tipo de estudio: Diagnostic_studies Límite: Female / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article